Alterations of DNA methylation in hematologic malignancies.
The DNA methylation profile of cancer cells is frequently characterized by global hypomethylation and simultaneous hypermethylation of selected CpG island gene promoters. In recent years, the epigenetic phenomenon of DNA promoter methylation has gained increasing recognition as an important mechanism for transcriptional inactivation of cancer related genes. Studies on both liquid and solid tumors have revealed myriad aberrant methylation events, some of which may provide important clues to the pathogenesis of these tumors. The identification of these methylation alterations and elucidation of the mechanistic events surrounding them are of prime importance, as the methylation status of cancer cells can now be manipulated in vivo with demethylating chemotherapeutics.
Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA. rush-1@medctr.osu.edu
Laura J
LJ
Rush
Christoph
C
Plass
D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D018899:CpG Islands; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D019337:Hematologic Neoplasms / Q000209:etiology / Q000235:genetics*; D006801:Humans; D011401:Promoter Regions, Genetic
D004273:DNA, Neoplasm